Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of High-dose Rate (HDR) Monotherapy for the Treatment of Low and Intermediate Risk Prostate Cancer

NCT02077335 is registered in ClinicalTrials.gov with CSSS de Gatineau as lead sponsor.

NCT NCT02077335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02077335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of High-dose Rate (HDR) Monotherapy for the Treatment of Low and Intermediate Risk Prostate Cancer
Lead sponsor
CSSS de Gatineau
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2014
Completion date
March 31, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer